Benfogamma 300mg 30 tablets — Made in Germany — Free Delivery

Pharmacodynamics. vitamin b1 is the main active ingredient. The fat-soluble precursor benfotiamine is converted in the body to biologically active thiamine pyrophosphate (TPP). TPF plays an active role in important functions of hydrocarbon exchange. in the process of converting pyruvate to acetyl coa and transketolase in the pentose phosphate cycle, thiamine pyrophosphate acts as a coenzyme. in addition, it takes part in the conversion of α-ketoglutarate to succinyl coa in the citric acid cycle. in the process of metabolism, there is an interaction with the rest of the vitamins of the b complex. in addition, cocarboxylase is a coenzyme of pyruvate dehydrogenase that plays a key role in glucose oxidation. Since energy in nerve cells is produced primarily through the oxidation of glucose, an adequate amount of thiamine is required for the functioning of nerve cells. in the case of an increase in glucose levels, the need for thiamine also increases. An insufficient amount of cocarboxylase leads to the accumulation of intermediate decomposition products in the blood and tissues, such as pyruvate, lactate and ketoglutarate, to the presence of which muscle tissue, myocardium and central nervous system react very painfully. Benfotiamine reduces the build-up of these toxic substances.

Determination in erythrocytes of the activity of enzymes dependent on thiamine diphosphate, for example, erythrocyte transketolase (ETC), and the level of their ability to activate (activation coefficient - α-ETA) are suitable for determining the status of vitamin B1. The concentration of ETC in blood plasma is 2-4 μg / 100 ml.

Pharmacokinetics. After oral administration of benfotiamine, dephosphorylation to S-benzoyl thiamine (SBT) occurs by phosphatases in the intestine. SBT is fat-soluble and therefore highly permeable. SBT is absorbed without any significant transformation of thiamine.

In contrast to thiamine, saturation kinetics are uncharacteristic for benfotiamine. Benfotiamine has a significantly higher bioavailability than water-soluble thiamine derivatives. In addition, benfotiamine is retained in tissues for a longer period.

Treatment of polyneuropathy and cardiovascular disorders (caused by vitamin B1 deficiency); clinically confirmed vitamin B1 deficiency or unbalanced nutrition (for example, beriberi), parenteral nutrition for a long time, "zero" diet, hemodialysis, impaired absorption of nutrients, increased need for vitamin B1 (for example, during pregnancy and lactation); chronic alcoholism (alcoholic cardiomyopathy, Wernicke's encephalopathy, Korsakov's syndrome).

Administered orally, the tablet is taken whole with a sufficient amount of liquid. for the treatment of vitamin B1 deficiency, take 1 tablet per day.

In the treatment of polyneuropathy, the recommended dose is 1 tablet per day for 3 weeks. Further treatment is determined depending on the obtained therapeutic effect.

Hypersensitivity to the components of the preparation; allergic reactions to vitamin B1.

Distributed by frequency: very often (1/10); (often (1/100, 1/10); infrequently (1/1000, 1/100); rarely (1/10 000, 1/1000); very rarely (1/10 000), including individual messages.

From the immune system: very rarely - hypersensitivity reactions, including anaphylactic shock, angioedema, allergic reactions (urticaria, exanthema); itching, hyperemia.

From the gastrointestinal tract: nausea, vomiting, abdominal pain, diarrhea.

Others: dizziness, headache, tachycardia.

Patients with a very rare hereditary galactose intolerance, lactase deficiency or malabsorption of glucose and galactose should not take this preparation.

Use during pregnancy and lactation. Due to the lack of sufficient experience in the use of the preparation during pregnancy, it should be used only in the case of laboratory-confirmed thiamine deficiency.

Children. The efficacy and safety of the preparation in children have not been established, therefore it is not used in pediatric practice.

The ability to influence the reaction rate when driving or working with other mechanisms. There are no warnings about prescribing the preparation to vehicle drivers and persons working with complex machinery. But it should be borne in mind that there may be side reactions, such as dizziness, headache and others (see SIDE EFFECTS), which reduce the reaction rate.

Interactions